Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2881317 | The Annals of Thoracic Surgery | 2008 | 8 Pages |
Abstract
Although neoadjuvant chemoradiation resulted in a significantly better complete pathologic response rate when compared with chemotherapy alone, that did not translate into a long-term survival advantage. Chemotherapy alone may be the preferred neoadjuvant modality to expedite resection, decrease operative mortality and postoperative complications, and improve survival in patients with locally advanced esophageal cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Theresa D. MD, Puja MD, Seth D. MD, Charles A. MD, Kamal A. MD, Joseph I. MD, Daniel L. MD,